Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation

Donor lymphocyte infusions (DLI) are a standard therapy following allogeneic hematopoietic cell transplantation (alloHCT) for preventing and treating leukemic relapse in high-risk patients, particularly those with myeloid malignancies such as acute myeloid leukemia (AML), chronic myeloid leukemia (C...

Full description

Saved in:
Bibliographic Details
Main Authors: London M. McDougal, Forrest L. Baker, Michael P. Gustafson, Emmanuel Katsanis, Richard J. Simpson
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563972/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849469887922044928
author London M. McDougal
Forrest L. Baker
Forrest L. Baker
Forrest L. Baker
Michael P. Gustafson
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Richard J. Simpson
Richard J. Simpson
Richard J. Simpson
Richard J. Simpson
author_facet London M. McDougal
Forrest L. Baker
Forrest L. Baker
Forrest L. Baker
Michael P. Gustafson
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Richard J. Simpson
Richard J. Simpson
Richard J. Simpson
Richard J. Simpson
author_sort London M. McDougal
collection DOAJ
description Donor lymphocyte infusions (DLI) are a standard therapy following allogeneic hematopoietic cell transplantation (alloHCT) for preventing and treating leukemic relapse in high-risk patients, particularly those with myeloid malignancies such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). However, the efficacy of DLI remains suboptimal and is accompanied by a significant risk of life-threatening graft-versus-host disease (GvHD), highlighting the urgent need for strategies that enhance graft-versus-leukemia (GvL) effects while mitigating GvHD. We propose that engaging donors in an acute bout of exercise during peripheral blood lymphocyte collection represents a promising strategy to enhance GvL activity whilst mitigating the risk of GvHD. A single bout of cardiorespiratory exercise triggers catecholamine- and β2-adrenergic receptor-dependent mobilization of effector lymphocytes into the bloodstream, significantly increasing the proportion of GvL-promoting NK-cells and γδ T-cells relative to total CD3+ T-cells while reducing GvHD-promoting naïve CD4+ and CD8+ T-cells. Preclinical evidence suggests that these exercise-mobilized lymphocytes infiltrate tumors, exhibit enhanced leukemic control in xenogeneic mice, and display transcriptomic and proteomic profiles indicative of heightened anti-tumor immunity, migration potential and cytokine responsiveness. In this narrative review, we evaluate the advantages and limitations of DLI as a post-alloHCT therapy and propose the novel concept of exercise-enhanced donor lymphocyte infusions (DLI-X) as a simple and cost-effective strategy to augment GvL effects in preventing and treating leukemic relapse. Additionally, we propose that enriching DLI-X with NK-cell-enhancing cytokines (e.g., IL-12, IL-15, and IL-18) will create a novel therapeutic product, termed DLI-XS, with enhanced potency for post-alloHCT applications. We also discuss how DLI-X and DLI-XS, can be leveraged in combination with other post-transplant interventions to maximize GvL effects while minimizing GvHD risks. Finally, we explore the critical role of donor fitness (e.g. V̇O2max) in potentially influencing clinical outcomes of alloHCT and post-transplant cell therapies. This comprehensive integration of DLI-X and DLI-XS into existing treatment paradigms represents a promising avenue for enhancing therapeutic outcomes in leukemic relapse post-alloHCT and will underscore the transformative potential of exercise as an accessible and cost-effective adjuvant for DLI.
format Article
id doaj-art-c83a79c106954d99a70fde06258e7265
institution Kabale University
issn 1664-3224
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-c83a79c106954d99a70fde06258e72652025-08-20T03:25:19ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.15639721563972Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantationLondon M. McDougal0Forrest L. Baker1Forrest L. Baker2Forrest L. Baker3Michael P. Gustafson4Emmanuel Katsanis5Emmanuel Katsanis6Emmanuel Katsanis7Emmanuel Katsanis8Emmanuel Katsanis9Richard J. Simpson10Richard J. Simpson11Richard J. Simpson12Richard J. Simpson13School of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ, United StatesSchool of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ, United StatesDepartment of Pediatrics, University of Arizona, Tucson, AZ, United StatesThe University of Arizona Cancer Center, Tucson, AZ, United StatesLaboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ, United StatesDepartment of Pediatrics, University of Arizona, Tucson, AZ, United StatesThe University of Arizona Cancer Center, Tucson, AZ, United StatesDepartment of Immunobiology, University of Arizona, Tucson, AZ, United StatesDepartment of Medicine, University of Arizona, Tucson, AZ, United StatesDepartment of Pathology, University of Arizona, Tucson, AZ, United StatesSchool of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ, United StatesDepartment of Pediatrics, University of Arizona, Tucson, AZ, United StatesThe University of Arizona Cancer Center, Tucson, AZ, United StatesDepartment of Immunobiology, University of Arizona, Tucson, AZ, United StatesDonor lymphocyte infusions (DLI) are a standard therapy following allogeneic hematopoietic cell transplantation (alloHCT) for preventing and treating leukemic relapse in high-risk patients, particularly those with myeloid malignancies such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). However, the efficacy of DLI remains suboptimal and is accompanied by a significant risk of life-threatening graft-versus-host disease (GvHD), highlighting the urgent need for strategies that enhance graft-versus-leukemia (GvL) effects while mitigating GvHD. We propose that engaging donors in an acute bout of exercise during peripheral blood lymphocyte collection represents a promising strategy to enhance GvL activity whilst mitigating the risk of GvHD. A single bout of cardiorespiratory exercise triggers catecholamine- and β2-adrenergic receptor-dependent mobilization of effector lymphocytes into the bloodstream, significantly increasing the proportion of GvL-promoting NK-cells and γδ T-cells relative to total CD3+ T-cells while reducing GvHD-promoting naïve CD4+ and CD8+ T-cells. Preclinical evidence suggests that these exercise-mobilized lymphocytes infiltrate tumors, exhibit enhanced leukemic control in xenogeneic mice, and display transcriptomic and proteomic profiles indicative of heightened anti-tumor immunity, migration potential and cytokine responsiveness. In this narrative review, we evaluate the advantages and limitations of DLI as a post-alloHCT therapy and propose the novel concept of exercise-enhanced donor lymphocyte infusions (DLI-X) as a simple and cost-effective strategy to augment GvL effects in preventing and treating leukemic relapse. Additionally, we propose that enriching DLI-X with NK-cell-enhancing cytokines (e.g., IL-12, IL-15, and IL-18) will create a novel therapeutic product, termed DLI-XS, with enhanced potency for post-alloHCT applications. We also discuss how DLI-X and DLI-XS, can be leveraged in combination with other post-transplant interventions to maximize GvL effects while minimizing GvHD risks. Finally, we explore the critical role of donor fitness (e.g. V̇O2max) in potentially influencing clinical outcomes of alloHCT and post-transplant cell therapies. This comprehensive integration of DLI-X and DLI-XS into existing treatment paradigms represents a promising avenue for enhancing therapeutic outcomes in leukemic relapse post-alloHCT and will underscore the transformative potential of exercise as an accessible and cost-effective adjuvant for DLI.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563972/fullhematological cancercell therapyexercise immunologyexercise oncologyadrenergic receptorscardiorespiratory fitness
spellingShingle London M. McDougal
Forrest L. Baker
Forrest L. Baker
Forrest L. Baker
Michael P. Gustafson
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Emmanuel Katsanis
Richard J. Simpson
Richard J. Simpson
Richard J. Simpson
Richard J. Simpson
Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
Frontiers in Immunology
hematological cancer
cell therapy
exercise immunology
exercise oncology
adrenergic receptors
cardiorespiratory fitness
title Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
title_full Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
title_fullStr Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
title_full_unstemmed Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
title_short Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
title_sort exercise mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation
topic hematological cancer
cell therapy
exercise immunology
exercise oncology
adrenergic receptors
cardiorespiratory fitness
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563972/full
work_keys_str_mv AT londonmmcdougal exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT forrestlbaker exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT forrestlbaker exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT forrestlbaker exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT michaelpgustafson exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT emmanuelkatsanis exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT emmanuelkatsanis exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT emmanuelkatsanis exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT emmanuelkatsanis exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT emmanuelkatsanis exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT richardjsimpson exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT richardjsimpson exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT richardjsimpson exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation
AT richardjsimpson exercisemobilizeddonorlymphocyteinfusionsenhancedwithcytokinestimulationforthepreventionandtreatmentofleukemicrelapseafterallogeneichematopoieticcelltransplantation